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Abstract
Leptin’s role in the regulation of food intake, energy expenditure and weight control are widely recognized, especially in
rodents. Likewise, the potential regulation of leptin secretion by insulin (and vice versa) has been of particular interest insofar
as these nutrient signals may have meaningful, even adverse (inter)actions, in diabetes. We used a freshly isolated rat adipose
tissue culture model to examine the effect of insulin, metformin and glibenclamide on basal and steroid-stimulated leptin
secretion. This model was selected because of its physiologic rates of leptin formation and preservation of potentially
significant cell^cell interactions compared to isolated cells. The basal rate of leptin secretion was 3.4 þ 1.2 ng/100 mg tissue/24
h. The addition of 100 nM dexamethasone or 400 nM hydrocortisone stimulated leptin secretion by 3^4 fold over basal (no
steroid). Insulin inhibited both basal and steroid-activated leptin secretion by 35^50%. This inhibition was present with either
1 mM pyruvate or 5 mM glucose as a substrate suggesting that glycolysis was not required. Metformin inhibited basal and
dexamethasone-stimulated leptin secretion in a dose dependent manner (50% inhibition occurred at 1 mM metformin) while
glibenclamide was ineffective. The effect of insulin on isolated fat cells versus fat tissue was tested in parallel. After 24 h in
culture, insulin inhibited leptin secretion similarly in both adipose preparations. The addition of 200 nM (3)N6-(2-
phenylisopropyl)-adenosine did not alter the results. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Leptin, the 16 kDa product of the ob gene, is an
adipocyte-derived hormone. Its essential role in the
regulation of food intake, energy expenditure and
total body fat stores is well recognized [1]. Further-
more, diverse neuroendocrine actions for leptin are
emerging [2]. A paradigm for leptin secretion, there-
fore, exists in which blood leptin levels fall when
caloric or energy intake is reduced and fat stores
decline. Conversely, blood leptin levels would rise
with feeding and expanded fat stores which, in
turn, would suppress appetite and enhance thermo-
genesis.
Recognizing the pivotal role of insulin in metabol-
ic homeostasis, the potential and manifold interac-
tions between leptin and insulin are of obvious inter-
est, especially in disease states such as insulin
resistant diabetes wherein blood insulin and leptin
levels are both frequently elevated. Under normal
physiologic conditions, and analogous to leptin, in-
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sulin levels rise with feeding and fall with fasting.
Inasmuch as leptin might alter insulin secretion or
its peripheral action and, on the other hand, insulin
might modify leptin’s secretion or action, the inter-
actions of these two hormones could have a pro-
found impact on energy metabolism [3].
We examined one aspect in this complex scenario,
namely, whether insulin has direct e¡ects on adipose
tissue leptin secretion. The antidiabetic agents met-
formin and glibenclamide were, furthermore, tested
for their potential direct regulation of adipose tissue
leptin secretion. We found that insulin causes a direct
inhibition of basal and steroid-stimulated leptin se-
cretion in cultured fat explants as well as isolated fat
cells ; metformin’s actions were analogous.
2. Materials and methods
2.1. Materials
Tissue culture media and ingredients were pur-
chased from Life Technologies (Grand Island, NY,
USA). General chemicals were from Sigma Chemical
Co. (St Louis, MO, USA).
2.2. Animals and tissue culture
Following euthanasia by cervical dislocation at be-
tween 9 and 10 a.m., adipose tissue was obtained
from the epididymal fat pads of three or four, 150^
250 g fed Sprague-Dawley rats. The tissue was ex-
cised and placed in sterile Dulbecco’s medium
(DMEM) containing 20 mM HEPES, pH 7.4,
5 mM glucose, 1% (w/v) bovine serum albumin
(BSA), 100 IU/ml penicillin and 100 Wg/ml strepto-
mycin. The total tissue was trimmed of visible vessels
and blood clots, minced into 2^4 mm3 pieces, mixed
gently and distributed into 1 cm plastic culture wells
such that each well contained 100 mg tissue in 1 ml
of the above DMEM. All groups were prepared in
quadruplicate. The samples were then incubated at
37‡C under 5% CO2 for 24 h and an aliquot of the
medium was removed to measure leptin. Fat cells
were cultured as noted previously [4]. For experi-
ments in which fat cells versus fat tissue were com-
pared in parallel, epididymal fat tissue from several
rats was pooled, minced and divided for either direct
culture (explants) or collagenase isolation (cells) pri-
or to culture.
2.3. Leptin secretion
Leptin was measured with a commercial rat leptin
radioimmunoassay (RIA) kit (Linco Research Inc.,
St. Charles, MO, USA). The sensitivity of this com-
mercial assay is 0.5 ng/ml leptin. The intra-assay co-
e⁄cient of variation was 3.4%.
2.4. Statistics
Fat explant or cell samples, pooled from three or
four rats (n = 1), were tested ( þ leptin, etc.) in quad-
ruplicate unless otherwise noted. Results are given as
a mean þ S.D. The paired Student’s t-test was used
for statistical analysis.
3. Results
3.1. Fat tissue culture
The viability of the cultured epididymal fat tissue
was established by several criteria: (1) The rate of
leptin secretion (ng secreted/g tissue/24 h) was com-
parable to published norms for both human adipose
tissue leptin secretion in vivo [5] and cultured rat
adipose tissue in vitro [6]. (2) After incubating the
fat tissue explants for 24 h, the fat pieces were colla-
Table 1
E¡ect of insulin on basal and dexamethasone-stimulated leptin
secretion from cultured rat adipose tissue
[Insulin]
nM
No dexamethasone With dexamethasone
(100 nM)
0 100 þ 0 (5) 100 þ 0 (5)
0.5 84 þ 4 (3)** 85 þ 3 (4)**
1.0 80 þ 13 (4) 73 þ 5 (4)**
100 73 þ 7 (5)** 63 þ 8 (5)**
Rat adipose tissue was incubated in the absence and presence
of 100 nM dexamethasone and with increasing concentrations
of insulin. Results are expressed as mean þ S.D. (n) relative to
the control (no insulin). The control rates of leptin formation
for the no dexamethasone versus 100 nM dexamethasone
groups were 4.1 þ 0.7 versus 11.9 þ 1.4 ng leptin secreted/100 mg
tissue/24 h. Statistically signi¢cant di¡erences due to insulin are
shown (**P6 0.01).
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genase-isolated to release free cells [7]. These isolated
cells were greater than 95% viable by propidium io-
dide staining. Moreover, using this collagenase tech-
nique, both the percent viable cells and the number
of cells isolated/100 mg of cultured tissue were no
di¡erent between the control and treatment groups.
(3) Leptin secretion rates were constant throughout
the 24 h incubation and linearly related to the
amount of tissue added (data not included).
3.2. Leptin secretion: the e¡ect of steroids, insulin and
substrate
Basal rates of leptin formation were 3.4 þ 1.2 ng
secreted/100 mg tissue/24 h. The addition of pharma-
cological amounts of steroid (100 nM dexametha-
sone) increased leptin formation 3.7 fold. Impor-
tantly, 400 nM hydrocortisone, also stimulated
leptin production to a similar extent over basal
(Fig. 1). In each case, basal- or steroid-stimulated,
100 nM insulin inhibited leptin secretion by 35^
50% compared to its respective pair without insulin.
The inhibition of leptin secretion by insulin was, fur-
thermore, dose dependent (Table 1). Neither leptin
secretion nor the e¡ect of insulin was altered by the
addition of the non-hydrolyzable adenosine agonist
(3)N6-(2-phenylisopropyl)-adenosine (data not in-
cluded).
The e¡ect of various culture medium substrate
conditions on basal and steroid-induced leptin was
examined. The ¢rst comparison was between 5 mM
glucose (DMEM) versus 25 mM glucose (DMEM).
Rates of leptin secretion in the absence of added
steroid (basal conditions) were 3.4. þ 1.2 versus
4.2 þ 1.2 ng secreted/100 mg tissue/24 h (n = 4) in
the presence of 5 versus 25 mM glucose, respectively
(P6 0.005). There was no di¡erence, however, when
these same groups (5 versus 25 mM glucose) were
compared in the presence of 100 nM dexamethasone
Fig. 1. Leptin secretion from cultured rat adipose tissue: e¡ect
of insulin and steroids. Rat epididymal adipose tissue was incu-
bated with (shaded bars) and without insulin (open bars) under
three conditions: no added steroid, 100 nM dexamethasone, or
400 nM hydrocortisone. Results are expressed as mean þ S.D.
(n = 4) relative to the control (no insulin or steroid). The con-
trol rate of leptin production was 3.4 þ 1.2 ng/100 mg tissue/24
h. Statistical di¡erences due to steroids alone (open bars, no in-
sulin) are versus the control (*P6 0.05, **P6 0.01). In each of
the three treatment groups, the e¡ect of insulin was tested.
These statistical di¡erences are given over the shaded bars
(*P6 0.05).
Fig. 2. Leptin secretion from cultured rat adipose tissue: e¡ect
of medium substrate conditions. Rat adipose tissue was incu-
bated under three medium substrate conditions (with no added
substrate, 1 mM pyruvate, or 5 mM glucose). In each of these
three groups, four conditions were tested as indicated in the
legend: control (no steroid or insulin added ^ open bars), 100
nM insulin (black bars), 100 nM dexamethasone (hatched bars),
and 100 nM insulin with 100 nM dexamethasone (shaded bars).
Within each of the three medium substrate groups, statistical
di¡erences are presented relative to the control (no insulin or
dexamethasone) within that set (*P6 0.05, **P6 0.01, n.s.
means not signi¢cant). The di¡erence between the insulin+dexa-
methasone versus dexamethasone pairs in each medium set is
not shown (for clarity) but was P6 0.05 for the ‘no substrate
group’ and P6 0.01 for both the ‘1 mM pyruvate’ and ‘5 mM
glucose’ groups. Data are given as mean þ S.D. (n = 3) and sta-
tistical comparisons are by paired t-test.
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(the rates of leptin secretion were 15.1 þ 8.9 versus
16.7 þ 10.4 ng/100 mg tissue/24 h, (n = 4) respec-
tively).
The culture medium was next adjusted to contain
either 1 mM pyruvate (no glucose), 5 mM glucose
(without pyruvate) or no added glucose or pyruvate
in DMEM (plus other basic medium additions as
described in Section 2), see Fig. 2. In each of these
three experimental groups, leptin secretion was ex-
amined with and without insulin and in the absence
and presence of 100 nM dexamethasone. Fig. 2 dem-
onstrates that the inhibitory e¡ect of insulin on leptin
secretion is present in each group except one (the
1 mM pyruvate group without added steroid).
3.3. Comparison of leptin secretion from cultured fat
cells versus fat tissue
In separate experiments, we compared leptin secre-
tion from cultured fat cells versus fat tissue in the
presence of 100 nM dexamethasone and with and
without 100 nM insulin. After 4 and 24 h in culture,
insulin inhibited leptin secretion from minced fat tis-
sue by 34 þ 13% and 17 þ 13%, respectively. In fat
cells, however, insulin stimulated leptin secretion by
27 þ 10% at 4 h but inhibited leptin secretion by
31 þ 10% at 24 h. Of importance, there was no
change in fat cell counts throughout the 24 h incu-
bation.
3.4. Leptin secretion: the e¡ect of metformin and
glibenclamide
Fig. 3 shows the e¡ect of 0.1 mM metformin and
5 WM glibenclamide on adipose tissue leptin secre-
tion. In each of the three panels in Fig. 3, leptin
secretion is examined with and without insulin and
in the absence and presence of 100 nM dexametha-
sone. The results are expressed relative to the control
(no added drug, insulin or steroid). The e¡ect of
insulin and steroid are comparable with the results
presented in Fig. 1. Therefore, only statistically sig-
ni¢cant comparisons for the action of metformin or
glibenclamide are presented. As is shown in Fig. 3,
only metformin caused a statistically signi¢cant inhi-
bition of dexamethasone-stimulated leptin secretion.
Metformin did not augment the inhibitory action of
insulin on leptin secretion. Fig. 4 demonstrates the
dose response curve for the action of metformin on
basal and dexamethasone-stimulated leptin secretion.
Fig. 3. E¡ect of metformin and glibenclamide on leptin secre-
tion from cultured rat adipose tissue. Rat adipose tissue was in-
cubated under three conditions: in the absence of added drug
or with either 0.1 mM metformin or 5 WM glibenclamide. In
each of the three conditions, the fat tissue was also incubated
with and without 100 nM insulin and 100 nM dexamethasone
as shown in the legend and described in Fig. 2. Results are ex-
pressed as mean þ S.D. (n = 4) relative to the control (no drug,
insulin, or dexamethasone). The control rate of leptin formation
was 3.9 ng/100 mg fat tissue/24 h. The only statistically signi¢-
cant e¡ect due to a drug was caused by metformin in the pres-
ence of dexamethasone (*P6 0.05).
Fig. 4. Dose response for e¡ect of metformin on adipose tissue
leptin secretion. Rat adipose tissue was cultured in the presence
and absence of 100 nM dexamethasone and with increasing
amounts of metformin. Results are given as mean þ S.D. (n = 4)
relative to the controls (no metformin, with or without dexa-
methasone). The rate of leptin formation was 2.3 þ 0.8 versus
8.0 þ 3.2, (n = 4) in the no steroid versus 100 nM dexamethasone
groups (without metformin), respectively. Metformin caused sig-
ni¢cant inhibition of leptin secretion (P6 0.05) at concentra-
tions greater than 0.5 mM (both with and without dexametha-
sone). At 0.1 mM metformin, only the dexamethasone-
stimulated leptin secretion was signi¢cantly inhibited (P6 0.05).
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Metformin caused a signi¢cant reduction in leptin
secretion at concentrations greater than 0.5 mM.
4. Discussion
The secretion of leptin by adipose tissue underlies
the mechanism by which the status of peripheral en-
ergy stores is communicated to the central nervous
system (CNS). Overall, the emerging picture is one in
which the serum leptin level re£ects both a stable
index of fat stores (the lipostat theory [8]) and yet
may be subject to regulation by other factors. Vari-
ous hormones, circulating compounds, and neuro-
genic signals have been examined for their potential
ability to regulate adipose leptin secretion, including
insulin, cAMP and glucocorticoids. Given the asso-
ciation between obesity and diabetes, we investigated
whether insulin or two antidiabetic agents, metfor-
min and glibenclamide, might alter adipose tissue
leptin secretion.
To date, there have been numerous in vitro studies
examining whether insulin regulates serum leptin
concentrations. Meaningful comparisons between
these diverse experimental designs requires consider-
ation of many factors, including, the animal and fat
depot of origin [9], whether collagenase isolated cells,
tissue explants or induced preadipocytes are em-
ployed [10,11], the incubation time, and also,
whether steroids are added [12,13].
Using collagenase-isolated cells from human fat
tissue (no steroids) [12,14,15], exposure to 100 nM
insulin, long-term, for 72 h, (two subjects, abdominal
fat) [14] or 96 h (six subjects, subcutaneous fat) [15]
increased leptin secretion by 900% and 190%, respec-
tively. In contrast, however, using isolated subcuta-
neous fat cells from surgical biopsies, an inhibitory
action of insulin on leptin production was ¢rst noted
[12]. These investigators found that insulin inhibited
dexamethasone-stimulated (but not basal) leptin se-
cretion by about 200% following prolonged culture
(after 36^48 h). This result is consistent with ours
wherein insulin (with dexamethasone) inhibited lep-
tin secretion from both fat cells and fat tissue at 24 h.
Using freshly isolated rat adipocytes exposure to
insulin either acutely (4 h or less) [13,16,17] or over
days [18,19] led to increased basal (non-steroid-
stimulated) leptin secretion. Other studies, using cul-
tured preadipocytes [20^23] have also found that in-
sulin enhances leptin secretion despite their very low
rates of leptin secretion [11].
The e¡ect of insulin on cultured adipose tissue ex-
plants (obtained from either rats or humans) di¡ers
from the above isolated fat cell studies. For example,
using either rat epididymal tissue [24] or human
omental and visceral tissue from lean and obese sub-
jects [6], steroid-stimulated but not basal ob mRNA
or leptin secretion was inhibited 40^50% by 100 nM
insulin when these tissues were cultured for 12^48 h.
These studies are consistent with our data. In addi-
tion, we demonstrate an inhibitory action of insulin
on leptin secretion in the absence of steroid as well as
with both high-dose (dexamethasone) and physio-
logic (hydrocortisone) steroids [25] (Fig. 1). Antithet-
ical to these fat explant studies, one study using rat
adipose tissue found that 700 nM insulin stimulated
basal leptin formation by 80% [16]. This fat explant
study di¡ers substantially, however, in that rat epi-
didymal fat was incubated acutely (4 h) and without
added steroid. To address this further we measured
the e¡ect of insulin on leptin secretion from isolated
rat fat cells versus fat tissue at 4 and 24 h in the
presence of 100 nM dexamethasone only. While in-
sulin consistently inhibited fat tissue, it caused a brief
27 þ 10% stimulation of leptin secretion at 4 h. Of
importance, however, similar to the fat explants, in-
sulin inhibited fat cell leptin secretion by 31 þ 6% at
24 h.
Taken together, the above-cited studies and ours
support the concept that while insulin appears to
have an early stimulatory e¡ect on leptin secretion,
the long-term in vitro action of insulin on leptin
secretion is inhibitory ([6,12,24], and this study), par-
ticularly in the presence of steroids. Perhaps the
short-term stimulation is related to the release of
preformed leptin [13,16]. Since cyclohexamide at-
tenuates the inhibition of ob mRNA in rat fat [24],
it may be that long-term exposure to insulin permits
su⁄cient accumulation of an intracellular inhibitor
to manifest this action. It is also compelling to con-
sider that paracrine actions, perhaps related to either
local proteases or the uptake or release of soluble
regulators from either fat cells or their surrounding
stromal cells [10] might play a role in modulating the
e¡ect of insulin on leptin secretion. These actions
would be best appreciated using intact fat tissue as
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opposed to dispersed cells. Along these lines, we
tested whether the 24 h extracellular conditioned me-
dium from fat cells versus fat tissue contained a solu-
ble, insulin-responsive factor that could degrade re-
combinant leptin. None, however, was detected (data
not included). Since we found that insulin inhibited
both fat cells and tissue at 24 h, paracrine etiologies
are less likely in the long-term.
We show that steroid-stimulated leptin secretion
was present in: the absence of glucose, and with
either 5 mM glucose, 25 mM glucose, or 1 mM py-
ruvate as a substrate (Fig. 2). Since the results with
pyruvate and glucose were equivalent, glycolysis is
not essential for the regulation of leptin secretion.
Our ¢ndings di¡er from those obtained using gel
matrix-cultured rat adipocytes [19] in which insulin
treatment and/or the attendant increase in glucose
metabolism were felt to augment leptin secretion. It
is impossible to reconcile di¡erences between our
study and one with such di¡ering methodology. Fur-
thermore, ¢nal cell counts and absolute rates of lep-
tin production are not provided [19]. Our data, fur-
thermore, suggest that while hyperglycemia per se
does not have a major e¡ect on maximally stimulated
adipose tissue leptin secretion, it may increase basal
secretion (23% in these in vitro studies).
Metformin and glibenclamide were tested to deter-
mine whether two antidiabetic agents with dissimilar
mechanisms of action might a¡ect adipose tissue lep-
tin secretion. Metformin inhibited both basal and
dexamethasone stimulated leptin secretion in a dose
dependent manner (Fig. 4), while glibenclamide was
ine¡ective. The ED50 for the observed inhibition by
metformin was 1 mM. This concentration is higher
than the in vivo therapeutic range for metformin
(12^100 WM [26] but well within the in vitro exper-
imental test range [27^29]. Insofar as metformin can
a¡ect adipocyte intracellular metabolism [26,30], this
antidiabetic agent may alter leptin secretion by the
same intracellular mechanism proposed above. Re-
cently, and consistent with our data, metformin
was shown to decrease serum leptin concentrations
in obese women with polycystic ovary syndrome [31].
Not surprisingly, glibenclamide, a sulfonylurea
whose primary in vivo action is at the Beta cell,
did not alter fat tissue leptin secretion (Fig. 3). The
increase in serum leptin found in NIDDM patients
treated with glibenclamide [32], could be related to
increased insulin, increased weight or improved gly-
cemic control (data not presented by the authors).
Also, while leptin and insulin both increased during
this drug trial [32], it remains undetermined whether
changes in leptin resistance contributed indepen-
dently to the rise in serum leptin.
In summary, a cultured fat explant model was
used to study the regulation of adipose tissue leptin
secretion. Insulin and metformin caused a dose de-
pendent inhibition of fat tissue leptin secretion both
with and without added steroids. This inhibition was
present with various substrates including glucose and
pyruvate suggesting that intrinsic glycolysis was un-
necessary for the response. These fat explant studies,
in concert with the previous studies using cultured fat
tissue [6,24], demonstrate an inhibitory action of in-
sulin on leptin secretion. While the mechanism for
this inhibition remains unknown, protein synthesis
appears to be required [24]. Taken together, these
cultured explant studies also suggest that paracrine
factors may be crucial in modulating the acute inhib-
itory e¡ect of insulin on leptin secretion since studies
in isolated fat cells have largely derived an opposite
conclusion. Along these lines, autocrine e¡ects of
leptin on adipocytes have been increasingly recog-
nized [33^36].
Finally, it is reasonable to propose that, at least in
the early phases of fat accretion, a direct inhibition
of leptin secretion by insulin could be an evolution-
ary survival advantage for mammals that rely on
erratic food supplies by maximizing fat accretion (re-
ducing satiety) when food is available.
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